iBIO appeals to industry veterans Marilyn Vetter and Harry Rowland
CHICAGO, January 10, 2022 / PRNewswire / – The Illinois Biotechnology Innovation Organization (iBIO), the professional association which represents 88,000 jobs Illinois’ life sciences sector, today announced the appointment of a new president and the addition of a new member to its board of directors. Marilyn Vetter, Group Vice President, U.S. Access Strategy at Horizon Therapeutics, moved from Vice President to Chairman of the Board of iBIO, and Harry D. Rowland, Ph.D., co-founder and CEO of Endotronix, has joined the board of directors. Vetter succeeds John larson, Managing Director, Alliance Management at AbbVie, who has just completed his two-year term.
“With the collective leadership of Marilyn and Harry and the experience of the industry, I am delighted for the future of iBIO as we increase our collaboration with state and federal decision makers to develop the state economy and helping our member companies transform lives through groundbreaking research, ”said John conrad, President and CEO, iBIO. “I am grateful to John larson for his leadership and commitment to iBIO and our community at a time of extraordinary growth and challenges. “
“The next three years are crucial for Illinois’ the life sciences industry as we expand the existing ecosystem, ”said Marilyn Vetter. “With this in mind, I am delighted to continue iBIO’s impactful public policy advocacy, as well as to connect our stakeholders with resources and engage our members to create a more resilient and inclusive life science community that focuses on pioneering innovative therapies for positive patient outcomes. . “
In her role as Chair of the Board of Directors, Vetter will work to advance iBIO’s strategic plan, which includes promoting the continued growth of Illinois’ the life sciences industry by strengthening relationships with decision makers and creating greater cohesion between life sciences companies. The association is also focused on advancing efforts to attract highly skilled and diverse talent and support the next generation of innovators.
Vetter joined Horizon in july 2014 as Senior Director, Government and Public Affairs. During her long career in the pharmaceutical industry, she has held numerous leadership positions in government affairs, managed markets and sales. Prior to joining Horizon, Vetter spent 15 years at Takeda Pharmaceuticals where she was Director of Government Affairs, leading the company’s government and public affairs efforts to Illinois and nine other Midwestern states, having held several positions in Takeda’s Market Access department. Prior to Takeda, Vetter spent seven years with Organon Inc. in a number of roles with increasing responsibilities in managed markets and sales. Previously, she was a presenter and reporter at the NBC affiliate in Bismarck, North Dakota where she covered national and local politics. She obtained a bachelor’s degree in communications and a minor in political science from the University of North Dakota at Grand Forks, ND
Harry D. Rowland is co-founder and CEO of Endotronix. Dr. Rowland has led the company’s operations, strategy and technology development since its inception. His vision was essential in raising $ 100 million in venture capital and strategic financing and building the business to more than 70 people. He obtained his doctorate in mechanical engineering from the Georgia Institute of Technology, a bachelor’s degree in mechanical engineering and a master’s degree in economics of University of California, Santa Barbara. Dr Rowland is the author of numerous journal articles in internationally renowned peer-reviewed publications, such as Science and Nano, with his work referenced in nearly 500 scientific papers, and he has presented his findings at several conferences. It has over 15 issued patents and several pending applications.
The Illinois Biotechnology Innovation Organization (iBIO) is a life sciences industry association that represents the 88,000 life sciences employees in Illinois. iBIO promotes the value of the industry to the public and policy makers; connects innovators with investment and talent; fuels collaboration and encourages the next generation of innovators and entrepreneurs to transform patients’ lives through groundbreaking research and work to develop the Illinois economy. To learn more about iBIO and its programs, visit http://www.ibio.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/illinois-biotechnology-innovation-organization-elects-new-board-chair-and-adds-new-board-member-301456837.html